Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 23Terminated 3Unknown 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 39Genitourinary 23Thoracic 11Breast 10Other hematologic neoplasm 8Lymphoid 4Sarcoma 3Head & Neck 3Endocrine 3Tumor-Agnostic 2Plasma cell 2Myeloid 2Gynecologic 2CNS 2Other solid neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Sarcoma, Kaposi 1Sarcoma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Sorafenib × Sarcoma × Clear all
NCT00880542 2020-08-10

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 5 charts
Sarcoma

Sarcoma

NCT00287495 2019-12-12

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
10 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT00734526 2018-11-09

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

M.D. Anderson Cancer Center

Phase 1 Terminated
18 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡